Aslan Stock Today

Equity ratings for Aslan Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of August 2021 and ending today, the 27th of October 2021. Click here to learn more.
Aslan Pharmaceuticals cannot be verified against its exchange. It appears that Aslan Pharmaceuticals is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Aslan Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Aslan Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aslan Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Aslan Pharmaceuticals is not yet fully synchronised with the market data
Aslan Pharmaceuticals generated a negative expected return over the last 90 days
Aslan Pharmaceuticals has high historical volatility and very poor performance
Aslan Pharmaceuticals has some characteristics of a very speculative penny stock
Aslan Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 189.71 K. Net Loss for the year was (19.87 M) with profit before overhead, payroll, taxes, and interest of 79.82 M.
Aslan Pharmaceuticals currently holds about 100.82 M in cash with (15.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96.
Aslan Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Aslan Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Aslan Pharmaceuticals SEC Filings
Aslan Pharmaceuticals SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameAslan Pharmaceuticals
Chairman of the Board, CEOCarl Firth  (View All)
Average Analyst Recommendation
Analysts covering Aslan Pharmaceuticals report their recommendations after researching Aslan Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Aslan Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Aslan Pharmaceuticals. The Aslan consensus assessment is calculated by taking the average forecast from all of the analysts covering Aslan Pharmaceuticals.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Aslan Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Aslan Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares198.4 M192.2 M
Sufficiently Up
Increasing
Slightly volatile
Weighted Average Shares Diluted198.5 M192.2 M
Sufficiently Up
Increasing
Slightly volatile
Total Assets25.1 M16.1 M
Way Up
Decreasing
Slightly volatile
Total Liabilities25.4 M26.2 M
Sufficiently Down
Increasing
Slightly volatile
Current Assets22.5 M15.5 M
Way Up
Decreasing
Slightly volatile
Current Liabilities9.5 M10.7 M
Moderately Down
Increasing
Slightly volatile
Total Debt18.2 M19.3 M
Notably Down
Increasing
Slightly volatile
Gross Margin0.80.78
Fairly Up
Decreasing
Slightly volatile
Asset Turnover0.07070.0711
Slightly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Aslan Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Aslan Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aslan Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aslan Pharmaceuticals' financial leverage. It provides some insight into what part of Aslan Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Aslan Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Aslan Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Aslan Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 15.54 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Aslan Pharmaceuticals has a current ratio of 17.94, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(16.24 Million)Share
Aslan Pharmaceuticals (ASLN) is traded on NASDAQ Exchange in USA. It is located in 83 Clemenceau Avenue and employs 18 people. Aslan Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 105.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aslan Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aslan Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Aslan Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 69.52 M outstanding shares of which 1.59 M shares are presently shorted by private and institutional investors with about 3.27 trading days to cover. Aslan Pharmaceuticals currently holds about 100.82 M in cash with (15.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96.
Check Aslan Pharmaceuticals Probability Of Bankruptcy

Aslan Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Aslan Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aslan Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aslan Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Total Clarity Wealth Management IncCommon Shares1000K
Rtw Investments LpCommon Shares3.2 M10.7 M
View Aslan Pharmaceuticals Diagnostics

Aslan Pharmaceuticals Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Aslan Pharmaceuticals market risk premium is the additional return an investor will receive from holding Aslan Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aslan Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Aslan Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Aslan Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.

Aslan Stock Against Markets

Picking the right benchmark for Aslan Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aslan Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aslan Pharmaceuticals is critical whether you are bullish or bearish towards Aslan Pharmaceuticals at a given time.
Aslan Pharmaceuticals cannot be verified against its exchange. It appears that Aslan Pharmaceuticals is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Aslan Pharmaceuticals Corporate Directors

Aslan Pharmaceuticals corporate directors refer to members of an Aslan Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Aslan Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Aslan Pharmaceuticals' board members must vote for the resolution. The Aslan Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Qingfeng Sun - Independent DirectorProfile
Damien Lim - DirectorProfile
Abel Ang - DirectorProfile
ChinFeng Sun - Independent DirectorProfile
Check out Trending Equities. Note that the Aslan Pharmaceuticals information on this page should be used as a complementary analysis to other Aslan Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Tools for Aslan Stock

When running Aslan Pharmaceuticals price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go